Summary: Roche and Sheba Medical Center’s ARC are collaborating to enhance NSCLC diagnosis and treatment using AI-driven digital pathology tools for faster, more precise patient care
Takeaways:
- Innovative Collaboration: Roche and Sheba Medical Center will co-develop digital pathology solutions on Roche’s navify platform to improve NSCLC diagnostics and personalize treatment.
- AI-Powered Insights: The partnership aims to integrate AI algorithms to detect molecular markers and predict patient responses to immunotherapies and targeted treatments.
- Broader Impact: While focusing initially on NSCLC, the collaboration plans to expand its advancements to other cancers, setting new standards in diagnostic accuracy and treatment efficiency.
Roche announced a collaboration with ARC, the innovation arm of Sheba Medical Center, to help improve the diagnosis and treatment of Non-Small Cell Lung Cancer (NSCLC).
By combining artificial intelligence (AI) with advanced digital pathology tools for personalized treatment, ARC aims to dramatically enhance the speed and precision of NSCLC patient diagnostics.
Digital Pathology Solutions for NSCLC Diagnosis
Under the agreement signed at the 2024 ARC Summit, Sheba Medical Center and Roche will co-develop innovative digital pathology solutions on the Roche’s navify Digital Pathology platform—with the objective to facilitate the detection of molecular markers in NSCLC, potentially enabling quicker and more accurate identification of patients eligible for immunotherapies and targeted treatments. By significantly reducing the time from diagnosis to treatment, the solution has the potential to save lives, allowing oncologists to act swiftly and with confidence.
Roche’s navify Digital Pathology platform will serve as the foundation for developing integrated algorithms that not only identify biomarkers but also predict how a patient may respond to specific treatments. This phase of the collaboration will initially focus on NSCLC, with plans to extend the application of these advancements to other cancers and diseases.
“We are thrilled to work with Sheba Medical Center and Prof. Iris Barshack, who is renowned for her leadership in digital pathology,” says Michael Rivers, VP and lifecycle leader of Roche Digital Pathology. “Together, we aim to demonstrate how advanced digital and AI technologies can significantly improve diagnostic accuracy and patient care. This collaboration provides the framework for the first of potentially many impactful projects designed to highlight the transformative benefits of digital pathology and innovative AI image analysis tools on cancer diagnosis and patient care.”
This collaboration builds on Sheba’s extensive experience in digital pathology and Roche’s clinical decision support capabilities, reflecting a shared commitment to advancing personalized medicine.
“This collaboration marks an exciting moment in our efforts to transform healthcare on a global scale. When one of the world’s leading digital pathology provider teams up with Sheba’s leading innovators in AI-driven diagnostics, it’s not just a statement of intent; it’s the start of a groundbreaking journey,” says Prof. Yitshak Kreiss, director general of Sheba Medical Center. “Together, we will be able to advance patient care in ways that were previously unimaginable. This collaboration will help us leverage advanced technologies to create new benchmarks for diagnostic accuracy and treatment efficacy.”
